Vita Therapeutics Bolsters Leadership to Advance Multiple Technology Platforms
Retrieved on:
Tuesday, March 22, 2022
Oncology, Health, Genetics, Research, Science, Biotechnology, Therapy, Regenerative medicine, Quality assurance, Biomedical sciences, Biotechnology, Neurodegeneration, Champions Oncology, University of Pittsburgh School of Medicine, Technology, Knowledge, Bankers Trust, Series, GMP, University, MANA, Johns Hopkins University, IPSC, Quality, Cell engineering, CMC, Faculty, Senior, Industry, B cell, Cancer, Certification, University of Washington Department of Bioengineering, Clinical trial, Genetics, Doctor of Philosophy, ASCP, Organizational culture, Vita, Xana, Manufacturing, Health technology, MS, Trust, StemCells, Inc., Wilfrid Sellars, Patient, Company, Muscular dystrophy, Organization, Precigen, Leadership, Microbiology, Technology transfer, BS, Food, US Foods, Regulation, Mesoblast, Translational research, LGMD, Management, Pharmaceutical industry, Research
In addition, Brown Advisory Chief Financial Officer and Chief Operating Officer David M. Churchill is newly-appointed to the Vita Therapeutics Board of Directors.
Key Points:
- In addition, Brown Advisory Chief Financial Officer and Chief Operating Officer David M. Churchill is newly-appointed to the Vita Therapeutics Board of Directors.
- His leadership roles at Brown Advisory will serve our company well as he provides knowledge and perspective around our growing infrastructure.
- Vita Therapeutics is a biotechnology company generating state-of-the-art cellular therapeutics for the treatment of debilitating neuromuscular diseases and cancers.
- Vita Therapeutics uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients.